scholarly journals Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine

2019 ◽  
Vol 164 (4) ◽  
pp. 1027-1036 ◽  
Author(s):  
Ainur Nurpeisova ◽  
Markhabat Kassenov ◽  
Nurkuisa Rametov ◽  
Kaissar Tabynov ◽  
Gourapura J. Renukaradhya ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Influenza Virus Vaccine ◽  
H5n1 Influenza Virus ◽  
H5n1 Influenza

Improvement of the H5N1 influenza virus vaccine strain to decrease the pathogenicity in chicken embryos

2011 ◽  
Vol 156 (4) ◽  
pp. 557-563 ◽  
Author(s):  
Norikazu Isoda ◽  
Yoshihiro Sakoda ◽  
Masatoshi Okamatsu ◽  
Yoshimi Tsuda ◽  
Hiroshi Kida
Keyword(s):  
Influenza Virus ◽  
Vaccine Strain ◽  
Virus Vaccine ◽  
Influenza Virus Vaccine ◽  
H5n1 Influenza Virus ◽  
Chicken Embryos ◽  
H5n1 Influenza

Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1

Vaccine ◽  
2019 ◽  
Vol 37 (28) ◽  
pp. 3722-3729 ◽  
Author(s):  
Christina Nicolodi ◽  
Franz Groiss ◽  
Oleg Kiselev ◽  
Markus Wolschek ◽  
Joachim Seipelt ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Influenza Virus Vaccine ◽  
H5n1 Influenza Virus ◽  
H5n1 Influenza

scholarly journals An Adjuvant for the Induction of Potent, Protective Humoral Responses to an H5N1 Influenza Virus Vaccine with Antigen-Sparing Effect in Mice

2010 ◽  
Vol 84 (17) ◽  
pp. 8639-8649 ◽  
Author(s):  
Yuk-Fai Lau ◽  
Lay-Hoon Tang ◽  
Amber W. McCall ◽  
Eng-Eong Ooi ◽  
Kanta Subbarao
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Seasonal Influenza ◽  
Influenza Virus Vaccine ◽  
Wild Type Virus ◽  
Wild Type ◽  
Vaccine Platform ◽  
Mucosal Adjuvant ◽  
H5n1 Influenza ◽  
Sparing Effect

ABSTRACT Intramuscular administration of inactivated influenza virus vaccine is the main vaccine platform used for the prevention of seasonal influenza virus infection. In clinical trials, inactivated H5N1 vaccines have been shown to be safe and capable of eliciting immune correlates of protection. However, the H5N1 vaccines are poorly immunogenic compared to seasonal influenza virus vaccines. Needle-free vaccination would be more efficient and economical in a pandemic, and the development of an effective and safe mucosal adjuvant will be an important milestone. A stabilized chemical analog of double-stranded RNA, PIKA, was previously reported to be a potent mucosal adjuvant in a murine model. While PIKA stimulates dendritic cells in vitro, little was known about its receptor and adjuvanting mechanism in vivo. In this study, we demonstrated that the immunostimulatory effect of PIKA resulted in an increased number of mature antigen-presenting cells, with the induction of proinflammatory cytokines at the inoculation site. In addition, coadministration of PIKA with a poorly immunogenic H5N1 subunit vaccine led to antigen sparing and quantitative and qualitative improvements of the immune responses over those achieved with an unadjuvanted vaccine in mice. The adjuvanted vaccine provided protection against lethal challenge with homologous and heterologous H5N1 wild-type viruses. Mice lacking functional TLR3 showed diminished cytokine production with PIKA stimulation, diminished antibody responses, and reduced protective efficacy against wild-type virus challenge following vaccination. These data suggest that TLR3 is important for the optimal performance of PIKA as an adjuvant. With its good safety profile and antigen-sparing effect, PIKA could be an attractive adjuvant for use in future pandemics.

scholarly journals Safety, Immunogenicity, and Protective Efficacy of an H5N1 Chimeric Cold-Adapted Attenuated Virus Vaccine in a Mouse Model

Viruses ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2420
Author(s):  
Weiyang Sun ◽  
Zhenfei Wang ◽  
Yue Sun ◽  
Dongxu Li ◽  
Menghan Zhu ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Influenza B Virus ◽  
Influenza B ◽  
H5n1 Influenza Virus ◽  
Cold Adapted ◽  
H5n1 Influenza ◽  
B Virus ◽  
Ha Protein ◽  
H5n1 Vaccine

H5N1 influenza virus is a threat to public health worldwide. The virus can cause severe morbidity and mortality in humans. We constructed an H5N1 influenza candidate virus vaccine from the A/chicken/Guizhou/1153/2016 strain that was recommended by the World Health Organization. In this study, we designed an H5N1 chimeric influenza A/B vaccine based on a cold-adapted (ca) influenza B virus B/Vienna/1/99 backbone. We modified the ectodomain of H5N1 hemagglutinin (HA) protein, while retaining the packaging signals of influenza B virus, and then rescued a chimeric cold-adapted H5N1 candidate influenza vaccine through a reverse genetic system. The chimeric H5N1 vaccine replicated well in eggs and the Madin-Darby Canine Kidney cells. It maintained a temperature-sensitive and cold-adapted phenotype. The H5N1 vaccine was attenuated in mice. Hemagglutination inhibition (HAI) antibodies, micro-neutralizing (MN) antibodies, and IgG antibodies were induced in immunized mice, and the mucosal IgA antibody responses were detected in their lung lavage fluids. The IFN-γ-secretion and IL-4-secretion by the mouse splenocytes were induced after stimulation with the specific H5N1 HA protein. The chimeric H5N1 candidate vaccine protected mice against lethal challenge with a wild-type highly pathogenic avian H5N1 influenza virus. The chimeric H5 candidate vaccine is thus a potentially safe, attenuated, and reassortment-incompetent vaccine with circulating A viruses.

scholarly journals Cross-Reactive Immunity to Clade 2 Strains of Influenza Virus A Subtype H5N1 Induced in Adults and Elderly Patients by Fluval, a Prototype Pandemic Influenza Virus Vaccine Derived by Reverse Genetics, Formulated with a Phosphate Adjuvant, and Directed to Clade 1 Strains

2008 ◽  
Vol 16 (4) ◽  
pp. 437-443 ◽  
Author(s):  
György Fazekas ◽  
Rita Martosne-Mendi ◽  
Istvan Jankovics ◽  
Istvan Szilvasy ◽  
Zoltan Vajo
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Reverse Genetics ◽  
Evolutionary Relationship ◽  
Influenza Virus Vaccine ◽  
Influenza Viruses ◽  
Antigenic Structure ◽  
Elderly Subjects ◽  
H5n1 Influenza ◽  
Clade 1

ABSTRACT High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious, cross-protective vaccine against H5N1 strains. Extensive genetic characterization of H5N1 strains has elucidated the natural evolutionary relationship of these strains, linking groups known as clades to a common ancestor. Although the clades and subclades probably differ sufficiently in their antigenic structure to warrant the preparation of different vaccines, there is some evidence that cross-reactive immunity can be afforded. We aimed to assess the immunogenicity of a clade 1 H5N1 (NIBRG-14) whole-virus vaccine with an aluminum phosphate adjuvant and to determine whether it can induce cross-reactive immunity against antigenically drifted clade 2 H5N1 strains, both those derived by reverse genetics and wild-type isolates. A total of 88 (44 adult and 44 elderly) subjects, who received one dose (6 μg) of the vaccine, were studied. As judged by U.S. and European licensing criteria based on hemagglutination inhibition, the subjects developed cross-reactive immunity against all studied H5N1 strains belonging to a clade different from that of the strain utilized to produce the vaccine. Our findings highlight the importance of stockpiling, since cross-immune reactions induced by prepandemic vaccines will likely reduce morbidity and mortality in case of a pandemic.

Sign in / Sign up

Export Citation Format

Share Document